The free dividend tracker to help you grow your wealth. Link your brokerage accounts and MerryDiv automatically syncs your holdings and dividends.
Data last updated: Sep 06, 2026
Snapshot (as of Sep 06, 2026): Viatris Inc. (VTRS) pays a $0.48 annual dividend ($0.12 quarterly), yielding 2.84% at $16.88/share. Next ex-dividend date 2026-08-21. 5 consecutive years of dividend growth. Source: Yahoo Finance, aggregated by MerryDiv.
Dividend Yield: 2.84%
Annual Dividend: $0.48 per share
Payout Ratio: -135.7%
Ex-Dividend Date: 2026-08-21
Dividend Frequency: quarterly
Sector: Healthcare
Years of Dividend History: 28
Viatris Inc. is a global pharmaceutical company with a portfolio spanning branded drugs, generics, biosimilars, and active pharmaceutical ingredients, anchored by recognizable names like EpiPen, Lipitor, and Lyrica. The Viatris Inc. dividend currently yields 2.84%, paid quarterly at $0.12 per share, with the next ex-dividend date on August 21, 2026. Trailing annual payments total $0.48 per share. VTRS stock carries a beta of 0.883, making it a lower-volatility option within the healthcare sector for income-focused investors.
Viatris Inc. pays out -135.7% of earnings as dividends, a payout ratio classified as conservative (below 40%) on a cash-flow basis, though the negative figure reflects a net loss rather than earnings coverage. Viatris Inc. dividend safety draws some support from the company's broad product base, which spans branded prescriptions, generics, and biosimilars across therapeutic areas including oncology, immunology, and cardiovascular disease, creating diversified revenue streams. The most significant pressure point is that negative reported earnings make traditional payout coverage metrics unreliable, leaving the dividend dependent on operational cash generation rather than net income.
Viatris Inc. dividend history shows a CAGR of 3.3% per year from 1995 to 2025. Per-share payments grew from $0.18 to $0.48 over that period (2026 is a partial year and excluded from the CAGR calculation). The largest annual increase in the window was 100.0% in 2022, though the data also contains at least one year-over-year decline exceeding 5%, so growth has not been linear.
| Period | CAGR | From | To |
|---|---|---|---|
| 3-Year | 0.0% | $0.48 (2022) | $0.48 (2025) |
| 5-Year | +32.0% | $0.12 (2007) | $0.48 (2025) |
| 10-Year | +10.9% | $0.17 (2002) | $0.48 (2025) |
VTRS stock fits dividend investors who want moderate income from a globally diversified pharmaceutical business without chasing high-yield risk. The current yield of 2.84% sits in the moderate (2-4%) range and runs slightly above the 5-year average of 2.67%, meaning income buyers are getting a marginally better entry yield than the historical norm. Five consecutive years of dividend increases show a recent pattern of discipline, though the 3.3% long-term CAGR means purchasing power growth is slow. The trade-off is clear: a broad product portfolio across generics, biosimilars, and branded drugs provides business diversification, but negative reported earnings make the payout harder to evaluate on conventional metrics.
| Payment Date | Amount per Share |
|---|---|
| 2026-08-21 | $0.1200 |
| 2026-05-22 | $0.1200 |
| 2026-03-09 | $0.1200 |
| 2025-11-24 | $0.1200 |
| 2025-08-22 | $0.1200 |
| 2025-05-23 | $0.1200 |
| 2025-03-10 | $0.1200 |
| 2024-11-22 | $0.1200 |
| 2024-08-23 | $0.1200 |
| 2024-05-23 | $0.1200 |
| Year | Total Dividends |
|---|---|
| 2026 | $0.3600 |
| 2025 | $0.4800 |
| 2024 | $0.4800 |
| 2023 | $0.4800 |
| 2022 | $0.4800 |
Project income from VTRS with the VTRS dividend calculator or track your full portfolio with the dividend tracker.